Literature DB >> 7944533

Pulmonary function in infants with cystic fibrosis: the effect of antibiotic treatment.

C S Beardsmore1, J R Thompson, A Williams, E K McArdle, G A Gregory, L T Weaver, H Simpson.   

Abstract

Since 1982 all infants born within the East Anglian Regional Health Authority have been screened for cystic fibrosis. Between April 1985 and April 1992 infants identified in this way have been entered into a randomised prospective controlled trial of antibiotic prophylaxis. Approximately half the infants received continuous oral flucloxacillin and the remainder received antibiotics when clinically indicated. Infants underwent tests of respiratory function at 3-4 months and at 1 year of age. Measurements of thoracic gas volume and airway conductance were made with an infant whole body plethysmograph, and maximum expiratory flow by the 'squeeze' technique. A total of 73 tests was performed of 42 infants. To facilitate comparisons, measurements were expressed as scores. The mean values of the scores for the two groups of infants fell within normal limits. There was no difference between the treatment groups at either age. A reduction in airways conductance was observed between the two tests.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7944533      PMCID: PMC1029944          DOI: 10.1136/adc.71.2.133

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  22 in total

1.  A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis.

Authors:  V A Loening-Baucke; E Mischler; M G Myers
Journal:  J Pediatr       Date:  1979-10       Impact factor: 4.406

2.  Partial expiratory flow-volume curves in infancy: technical aspects.

Authors:  M Silverman; A Prendiville; S Green
Journal:  Bull Eur Physiopathol Respir       Date:  1986 May-Jun

3.  Ventilatory function in infants with cystic fibrosis. Physiological assessment of halation therapy.

Authors:  P D Phelan; M Gracey; H E Williams; C M Anderson
Journal:  Arch Dis Child       Date:  1969-06       Impact factor: 3.791

4.  Screening for cystic fibrosis by died blood spot trypsin assay.

Authors:  A F Heeley; M E Heeley; D N King; J A Kuzemko; M P Walsh
Journal:  Arch Dis Child       Date:  1982-01       Impact factor: 3.791

5.  Involuntary smoking and incidence of respiratory illness during the first year of life.

Authors:  F A Pedreira; V L Guandolo; E J Feroli; G W Mella; I P Weiss
Journal:  Pediatrics       Date:  1985-03       Impact factor: 7.124

6.  Serial lung function studies in cystic fibrosis in the first 5 years of life.

Authors:  S Godfrey; M Mearns; G Howlett
Journal:  Arch Dis Child       Date:  1978-01       Impact factor: 3.791

7.  Infants with cystic fibrosis: pulmonary function at diagnosis.

Authors:  R S Tepper; P Hiatt; H Eigen; P Scott; J Grosfeld; M Cohen
Journal:  Pediatr Pulmonol       Date:  1988

8.  Determinants of forced expiratory flows in newborn infants.

Authors:  L M Taussig; L I Landau; S Godfrey; I Arad
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1982-11

9.  Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period.

Authors:  L T Weaver; M R Green; K Nicholson; J Mills; M E Heeley; J A Kuzemko; S Austin; G A Gregory; A E Dux; J A Davis
Journal:  Arch Dis Child       Date:  1994-02       Impact factor: 3.791

10.  Parental smoking and respiratory illness in infancy.

Authors:  D M Fergusson; L J Horwood; F T Shannon
Journal:  Arch Dis Child       Date:  1980-05       Impact factor: 3.791

View more
  10 in total

Review 1.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 2.  Systematic review of antistaphylococcal antibiotic therapy in cystic fibrosis.

Authors:  K McCaffery; R E Olver; M Franklin; S Mukhopadhyay
Journal:  Thorax       Date:  1999-05       Impact factor: 9.139

3.  Early detection of cystic fibrosis lung disease: multiple-breath washout versus raised volume tests.

Authors:  Sooky Lum; Per Gustafsson; Henrik Ljungberg; Georg Hülskamp; Andrew Bush; Siobhán B Carr; Rosemary Castle; Ah-Fong Hoo; John Price; Sarath Ranganathan; John Stroobant; Angie Wade; Colin Wallis; Hilary Wyatt; Janet Stocks
Journal:  Thorax       Date:  2006-11-22       Impact factor: 9.139

4.  Prophylactic anti-staphylococcal antibiotics for cystic fibrosis.

Authors:  Margaret Rosenfeld; Oli Rayner; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2020-09-30

Review 5.  Monitoring early inflammation in CF. Infant pulmonary function testing.

Authors:  Jack K Sharp
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

6.  Lung function from infancy to school age in cystic fibrosis.

Authors:  C S Beardsmore
Journal:  Arch Dis Child       Date:  1995-12       Impact factor: 3.791

Review 7.  Novel end points for clinical trials in young children with cystic fibrosis.

Authors:  Shannon J Simpson; Lauren S Mott; Charles R Esther; Stephen M Stick; Graham L Hall
Journal:  Expert Rev Respir Med       Date:  2013-06       Impact factor: 3.772

8.  Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis.

Authors:  Drucy Borowitz; Karen A Robinson; Margaret Rosenfeld; Stephanie D Davis; Kathryn A Sabadosa; Stephanie L Spear; Suzanne H Michel; Richard B Parad; Terry B White; Philip M Farrell; Bruce C Marshall; Frank J Accurso
Journal:  J Pediatr       Date:  2009-12       Impact factor: 4.406

Review 9.  Oral anti-pseudomonal antibiotics for cystic fibrosis.

Authors:  Tracey Remmington; Nikki Jahnke; Christian Harkensee
Journal:  Cochrane Database Syst Rev       Date:  2016-07-14

10.  Clinical outcomes associated with Staphylococcus aureus and Pseudomonas aeruginosa airway infections in adult cystic fibrosis patients.

Authors:  Heather G Ahlgren; Andrea Benedetti; Jennifer S Landry; Joanie Bernier; Elias Matouk; Danuta Radzioch; Larry C Lands; Simon Rousseau; Dao Nguyen
Journal:  BMC Pulm Med       Date:  2015-06-21       Impact factor: 3.317

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.